January 8, 2014

News stories about doctor shopping and prescription pad pilfering in pursuit of a pain-pill induced high have become commonplace, prompting many legislators and regulators to consider further restrictions on pain medicines like hydrocodone compounds. But there may be a story that’s not being told — that the patients who suffer from chronic pain and need that hydrocodone to reclaim their lives are being stigmatized. The prevalence of pain pill abuse has left in its wake as many as 116 million legitimate pain sufferers who are finding it more difficult to access their therapies.

October 21, 2015

“This crisis is taking lives — it’s destroying families and shattering communities all across the country,” President Obama said in remarks at a community forum meant to kick off his administration’s new push to curb opioid abuse. 

September 23, 2015

CVS/pharmacy has also renewed its Medication Disposal for Safer Communities Program.

September 18, 2015

The Centers for Disease Control and prevention this week announced that a new draft guideline for prescribing opioids to patients with chronic pain was in the works. 

September 11, 2015

Egalet Corporation on Thursday launched (oxycodone HCI) in the U.S.

September 10, 2015

However, patients in the 10-17 years age group also showed the greatest improvement in appropriate prescription drug use compared to all other age groups over a four-year period.

August 24, 2015

Camber Pharmaceuticals last week announced its introduction of its entecavir tablet in 0.5- and 1-mg dosage strengths.

August 19, 2015

A study conducted by researchers at Johns Hopkins Bloomberg School of Public Health has found that Florida’s legislative efforts to curb opioid abuse seem to be having their desired effect. 

August 17, 2015

The website includes sections about the importance of preventing abuse of prescription drugs and outlines the Food and Drug Administrations guidelines on abuse-deterrent labeling. 

August 10, 2015

According to the Substance Abuse Mental Health Services Administration, more than 24.5 million people age 12 or older in the U.S. (9.4% of the population) live with substance use disorders.

July 29, 2015

The Consumer Healthcare Products Association expressed support for the DXM Abuse Prevention Act, introduced into the U.S. House of Representatives by U.S. Reps. Bill Johnson, R-Ohio, and Doris Matsui, D-Calif., on Wednesday.

June 10, 2015

Despite high-profile efforts to implement abuse-deterrent labels and properties on brand-name opioids, advisory company Avalere Health’s latest research notes a key blind spot in the efforts — accessibility.

May 19, 2015

Pharmacy Quality Alliance has endorsed three new performance measures to assess the use of opioids. 

April 10, 2015

Tennessee on Wednesday became the eighth state to restrict DXM sales. 

March 31, 2015

The drug is Food and Drug Administration-approved to treat opioid-induced constipation in adults with chronic, non-cancer pain. 

March 11, 2015

Mylan expanded its portfolio of generic products with the U.S. launch of buprenorphine hydrochloride sublingual tablets in 2-mg and 8-mg strengths, the generic version of Subutex from Reckitt Benckiser.

February 27, 2015

Epic Pharma on Friday launched two generics: a schedule II pain reliever and a calcium channel blocker. 

February 25, 2015

In 10 years, the percentage of opioid analgesic users who used an opioid analgesic stronger than morphine increased from 17% to 37%, NCHS reported Wednesday. 

February 20, 2015

Actavis on Friday gained approval for a generic version of Reckitt Benckiser's Subutex, indicated for the treatment of opioid dependence.

February 3, 2015

Zogenix last week announced that the Food and Drug Administration approved a new formulation of the company's Zohydro ER (hydrocodone bitartrate) extended-release capsules, CII.

January 26, 2015

Purdue Pharma on Monday announced the launch of Hysingla ER (hydrocodone bitartrate) extended-release tablets CII. According to the company, the once-daily drug is the first and only hydocodone product to be recognized by the Food and Drug Administration as having properties that deter misuse and abuse via chewing, snorting and injection.

January 14, 2015

Egalet Corp. last week announced the licensing and acquisition of two pain products. Egalet has agreed to license worldwide rights to Oxaydo (oxycodone HCI, USP) tablets for oral use only -CII, the first and only approved immediate-release oxycodone product formulated to deter abuse via snorting from Acura Pharmaceuticals, the company stated.

December 16, 2014

Use of cigarettes, alcohol and abuse of prescription pain relievers among teens has declined since 2013, while marijuana use rates were stable, according to the 2014 Monitoring the Future survey, released Tuesday.

December 9, 2014

From 2009 to 2013, the number of Americans using prescription opiates declined 9.2%, yet both the number of opioid prescriptions filled and the number of days of medication per prescription rose more than 8% in that time period.